| 前收市價 | 62.60 |
| 開市 | 無 |
| 買盤 | 53.60 |
| 賣出價 | 58.50 |
| 拍板 | 95.00 |
| 到期日 | 2024-12-20 |
| 今日波幅 | 62.60 - 62.60 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 6 |
ZacksApellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug
Apellis (APLS) declines as CHMP issues a second negative opinion for the approval of intravitreal pegcetacoplan to treat GA in the EU. The company plans to seek re-examination of the same.
ZacksApellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study
Apellis (APLS) rises 3.3% as the treatment of GA patients with Syfovre demonstrates a visual function benefit in a prespecified endpoint at month 36 in a late-stage, long-term extension study.
ZacksWhy Is Apellis Pharmaceuticals (APLS) Down 1.9% Since Last Earnings Report?
Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
